Shi Yin Wong1, Ainsley Ryan Yan Bin Lee1, Aaron Hon Jiun Sia1, Yu Jun Wo1, Yao Hao Teo1, Yao Neng Teo1, Nicholas L Syn1, Ching-Ching Ong1,2, Lynette L Teo1,2, Tiong-Cheng Yeo1,3, Kian-Keong Poh1,3, William K Kong1,3, Raymond C Wong1,3, Ching-Hui Sia4,5. 1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Department of Diagnostic Imaging, National University Hospital, Singapore, Singapore. 3. Department of Cardiology, National University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 9, Singapore, 119228, Singapore. 4. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ching_hui_sia@nuhs.edu.sg. 5. Department of Cardiology, National University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 9, Singapore, 119228, Singapore. ching_hui_sia@nuhs.edu.sg.
Abstract
PURPOSE: Recent trials suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and heart failure-related hospitalisations. We examined whether and how GLP-1RAs affect cardiac function in cardiovascular and metabolic diseases including type 2 diabetes, heart failure and post-myocardial infarction. METHODS: In this PRISMA-adherent systematic review and meta-analysis, three databases were searched from inception to July 2021 and registered on PROSPERO (CRD42021259661). RESULTS: 20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed. Among type 2 diabetes patients, GLP-1RA resulted in improved systolic function measured by circumferential strain (mean difference [MD]= -5.48; 95% CI: -10.47 to -0.49; P= 0.03; I2= 89%) and diastolic dysfunction measured by E / A (MD= -0.15; 95% CI: -0.25 to -0.05; P= 0.003; I2= 0%). For post-myocardial infarction patients, GLP-1RA reduced infarct size (g) (MD= -5.36; 95% CI: -10.68 to -0.04; P= 0.05; I2= 78%). Liraglutide, but not exenatide, demonstrated improved systolic function, by increasing left ventricular ejection fraction (MD= 4.89; 95% CI: 3.62 to 6.16; P< 0.00001; I2= 0%) and reducing left ventricular end-systolic volume (MD= -4.15; 95% CI: -7.49 to -0.81; P = 0.01; I2= 0%). Among heart failure patients, no significant changes were noted. CONCLUSION: GLP-1RA drugs may improve systolic and diastolic function in type 2 diabetes and reduce infarct size post-acute myocardial infarction with no demonstrable effect on cardiac function in heart failure. Tailored recommendations for the use of GLP-1RAs for cardioprotection should be considered for each patient's condition.
PURPOSE: Recent trials suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a cardioprotective role by reducing major adverse cardiac events, stroke mortality and heart failure-related hospitalisations. We examined whether and how GLP-1RAs affect cardiac function in cardiovascular and metabolic diseases including type 2 diabetes, heart failure and post-myocardial infarction. METHODS: In this PRISMA-adherent systematic review and meta-analysis, three databases were searched from inception to July 2021 and registered on PROSPERO (CRD42021259661). RESULTS: 20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed. Among type 2 diabetes patients, GLP-1RA resulted in improved systolic function measured by circumferential strain (mean difference [MD]= -5.48; 95% CI: -10.47 to -0.49; P= 0.03; I2= 89%) and diastolic dysfunction measured by E / A (MD= -0.15; 95% CI: -0.25 to -0.05; P= 0.003; I2= 0%). For post-myocardial infarction patients, GLP-1RA reduced infarct size (g) (MD= -5.36; 95% CI: -10.68 to -0.04; P= 0.05; I2= 78%). Liraglutide, but not exenatide, demonstrated improved systolic function, by increasing left ventricular ejection fraction (MD= 4.89; 95% CI: 3.62 to 6.16; P< 0.00001; I2= 0%) and reducing left ventricular end-systolic volume (MD= -4.15; 95% CI: -7.49 to -0.81; P = 0.01; I2= 0%). Among heart failure patients, no significant changes were noted. CONCLUSION: GLP-1RA drugs may improve systolic and diastolic function in type 2 diabetes and reduce infarct size post-acute myocardial infarction with no demonstrable effect on cardiac function in heart failure. Tailored recommendations for the use of GLP-1RAs for cardioprotection should be considered for each patient's condition.
Authors: Michael A Nauck; Juris J Meier; Matthew A Cavender; Mirna Abd El Aziz; Daniel J Drucker Journal: Circulation Date: 2017-08-29 Impact factor: 29.690
Authors: Scott D Solomon; Nagesh Anavekar; Hicham Skali; John J V McMurray; Karl Swedberg; Salim Yusuf; Christopher B Granger; Eric L Michelson; Duolao Wang; Stuart Pocock; Marc A Pfeffer Journal: Circulation Date: 2005-12-05 Impact factor: 29.690
Authors: E Wu; J T Ortiz; P Tejedor; D C Lee; C Bucciarelli-Ducci; P Kansal; J C Carr; T A Holly; D Lloyd-Jones; F J Klocke; R O Bonow Journal: Heart Date: 2007-12-10 Impact factor: 5.994
Authors: Graham S Hillis; Jacob E Møller; Patricia A Pellikka; Bernard J Gersh; R Scott Wright; Steve R Ommen; Guy S Reeder; Jae K Oh Journal: J Am Coll Cardiol Date: 2004-02-04 Impact factor: 24.094
Authors: Steffen E Petersen; Nay Aung; Mihir M Sanghvi; Filip Zemrak; Kenneth Fung; Jose Miguel Paiva; Jane M Francis; Mohammed Y Khanji; Elena Lukaschuk; Aaron M Lee; Valentina Carapella; Young Jin Kim; Paul Leeson; Stefan K Piechnik; Stefan Neubauer Journal: J Cardiovasc Magn Reson Date: 2017-02-03 Impact factor: 5.364